Icotyde
What Icotyde is used for
Icotyde is indicated for the treatment of moderate to severe plaque psoriasis in adults, and adolescents 12 years of age and older and weighing at least 40 kg, who are candidates for systemic therapy
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Icotyde
- Active substance
- icotrokinra hydrochloride
- Disease area
- Psoriasis
- Medicine group
- Immunosuppressants
- ATC code
- L04AC28
- Marketing authorisation holder
- Janssen-Cilag International
- Authorised in the EU since
- 2026
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Icotyde used for?
Icotyde is indicated for the treatment of moderate to severe plaque psoriasis in adults, and adolescents 12 years of age and older and weighing at least 40 kg, who are candidates for systemic therapy
What is the active substance in Icotyde?
Icotyde contains icotrokinra hydrochloride.
Who makes Icotyde?
The EU marketing authorisation holder is Janssen-Cilag International.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU